Biohaven Pharmaceutical Holding Company Ltd. Stock
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.37 USD | -2.81% | +4.71% | -75.38% |
May. 15 | Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing | MT |
May. 14 | Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing | MT |
Financials (USD)
Sales 2020 | 63.63 | Sales 2021 | 462.51 | Capitalization | 9.03B |
---|---|---|---|---|---|
Net income 2020 | -767M | Net income 2021 | -847M | EV / Sales 2020 | 87,534,473 x |
Net Debt 2020 | 432M | Net Debt 2021 | 860M | EV / Sales 2021 | 21,377,123 x |
P/E ratio 2020 |
-6.56
x | P/E ratio 2021 |
-10.5
x | Employees | 928 |
Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 90.13% |
1 day | -2.81% | ||
Current month | -75.38% | ||
Current year | -75.38% |
Managers | Title | Age | Since |
---|---|---|---|
Paloma Moraleda
PSD | President | - | 22-10-02 |
Jon Blaskovich
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 17-10-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paloma Moraleda
PSD | President | - | 22-10-02 |
Gastón Ortega
BRD | Director/Board Member | - | 22-10-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.97% | 0 M€ | 0.00% | - | |
0.11% | 9 M€ | -.--% | - | |
0.06% | 744 M€ | +9.63% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 37.37 | -2.83% | 807,842 |
24-05-16 | 38.46 | +3.72% | 595,667 |
24-05-15 | 37.08 | -0.43% | 1,019,166 |
24-05-14 | 37.24 | +10.24% | 1,308,042 |
24-05-13 | 33.78 | -5.35% | 2,012,433 |
Delayed Quote Nyse, May 17, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-75.38% | 541M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- BHVN Stock